Levonance 30 (Ethinylestradiol, Levonorgestrel)

The two hormones act together on the hypothalamic‑pituitary‑ovarian axis. Ethinylestradiol suppresses the release of follicle‑stimulating hormone, while levonorgestrel suppresses luteinizing hormone, preventing the mid‑cycle surge that triggers ovulation. Additionally, levonorgestrel thickens cervical mucus and alters the endometrium, reducing the chance of implantation.

The dosing regimen for Levonance 30 is determined by the prescribing healthcare professional. Typically, the product is taken once daily at the same time each day, following the specific schedule indicated on the prescription label.

Levonance 30 is contraindicated in pregnancy (Category X) and should not be started or continued by women who are pregnant. While limited data exist for breastfeeding, the progestin component may pass into breast milk; clinicians usually advise caution and consider alternative contraception for nursing mothers.

To order Levonance 30, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levonance 30 contains the standard dose combination of ethinylestradiol and levonorgestrel, a widely used progestin. Its efficacy, safety profile, and side‑effect spectrum are comparable to other products in the same class, though individual tolerability may vary based on patient-specific factors.

Levonance 30 tablets should be stored at ambient temperature, below 25 °C, in their original blister pack. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability throughout its shelf life.

Levonance 30 is taken orally, usually once a day, at the same time each day. The tablets are swallowed whole with water and should be started according to the prescribing clinician’s instructions, often on the first day of the menstrual cycle.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe hypertension, hepatic adenoma, and rare allergic reactions. Patients should seek immediate medical attention if they experience unexplained leg pain, shortness of breath, severe headache, visual changes, or signs of an allergic reaction.

Women with known or suspected pregnancy, active or past thromboembolic disease, estrogen‑dependent tumors, uncontrolled hypertension, severe liver disease, or those who smoke and are over 35 years old should avoid Levonance 30. A thorough medical history is essential before initiating therapy.